
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson demonstrated robust financial performance in its second quarter of 2025, reporting innovative medicine revenues of $15.20 billion, surpassing consensus expectations, which reflects strong operational growth. The company's management has raised its full-year 2025 sales guidance to a range of $93.2 billion to $93.6 billion, attributing approximately $900 million of this increase to operational strength and another $1.1 billion to favorable currency fluctuations. With anticipations of stronger operational sales growth in the second half of 2025 compared to the first half and positive momentum in its MedTech and Vision segments, Johnson & Johnson is poised for continued growth through 2026.
Bears say
Johnson & Johnson's stock outlook is negatively influenced by a projected decline in organic revenue growth, particularly due to lower contributions from its pharmaceutical pipeline and the impact of upcoming patent expirations expected to lead to less than $57 billion in revenue by 2025. The company's MedTech segment is facing headwinds from competitive pressures, which may hinder the uptake of new products, and concerns over M&A integration could disrupt operational efficiency. Additionally, higher litigation and settlement costs, combined with disappointing product launches, create further risks that could adversely affect sales and earnings forecasts.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares